ELOXX PHARMACEUTICALS, INC. Deferred Revenue
ELOXX PHARMACEUTICALS, INC. (ELOX) had Deferred Revenue of $150.00 thousand as of 2014-12-31, per its 10-Q filed 2015-02-17.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2015-02-17
- 2014-12-31: Deferred Revenue $150.00K.
- 2014-06-30: Deferred Revenue $0.00.
| Period end | Deferred Revenue |
|---|---|
| 2014-12-31 | $150.00K 10-Q · filed 2015-02-17 |
| 2014-06-30 | $0.00 10-Q · filed 2015-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |